SeqLL Announces Formation of Scientific Advisory Board – Benzinga – Press Release

BILLERICA, Mass., March 21, 2022 (GLOBE NEWSWIRE) — SeqLL Inc. (“SeqLL” or the “Company”) SQL SQLLW))), a technology company providing life sciences instrumentation and research services for collaborative partnerships, today announced the formation of a Scientific Advisory Board (“SAB”) comprised of distinguished and world-renowned leaders of the scientific community. The SAB will discuss with management potential new development opportunities that leverage the Company’s unique True Single Molecule Sequencing (tSMS®) technology across the “omics” fields, as well as advise management with their existing collaborative, scientific, & development partnerships. Each leader has previously utilized the tSMS platform and will leverage their expertise to provide valuable insight to our company.

“We are privileged to be working with this distinguished and talented group of scientific advisors as we expand the reach of our tSMS technology,” said Daniel Jones, CEO, President, and Co-Founder of SeqLL. “These advisors bring valuable scientific insight and industry contacts to our work and will assist us in becoming a world-class leader in creating novel assets with our true single molecule sequencing technology.”

Leaders of the SeqLL Scientific Advisory Board include:

Claes Wahlestedt, M.D., Ph.D., Chairman of the SAB. Director of the Center for Therapeutic Innovation, Leonard M. Miller School of Medicine, University of Miami. Dr. Wahlestedt has a long-standing academic as well as big pharma career in drug discovery, genomics and epigenetics, and has pioneered various translational efforts in these fields. From 2005 to 2011, Dr. Wahlestedt was a professor and a director at The Scripps Research Institute. Prior to that he founded and ran the genomics and bioinformatics center at the Karolinska Institute (a joint venture with Pharmacia/Pfizer). Among companies he has co-founded are CuRNA (now part of Opko Health/Camp4), based on his patent for targeting…